US 4123403A
· Warner
· 1978
[cited by applicant]
US 4502888A
· Leng
· 1985
[cited by applicant]
US 5681584A
· Savastano et al.
· 1997
[cited by applicant]
US 5914122A
· Otterbeck et al.
· 1999
[cited by applicant]
US 5932249A
· Gruber et al.
· 1999
[cited by applicant]
US 6200602B1
· Watts et al.
· 2001
[cited by applicant]
US 6228396B1
· Watts
· 2001
[cited by applicant]
US 6239120B1
· Hallgren et al.
· 2001
[cited by applicant]
US 6423340B1
· Ulmius
· 2002
[cited by applicant]
US 6534549B1
· Newton et al.
· 2003
[cited by applicant]
US 8491932B2
· Watts et al.
· 2013
[cited by applicant]
US 8945616B2
· Murty et al.
· 2015
[cited by applicant]
US 20020192282A1
· Beckert et al.
· 2002
[cited by applicant]
US 20050089571A1
· Beckert et al.
· 2005
[cited by applicant]
US 20060057200A1
· Schaeffler
· 2006
[cited by applicant]
US 20090004281A1
· Nghiem et al.
· 2009
[cited by applicant]
US 20110189293A1
· Padval
· 2011
[cited by applicant]
US 20140088052A1
· Biswal et al.
· 2014
[cited by applicant]
US 20150118296A1
· Kulkarni et al.
· 2015
[cited by applicant]
US 20170100411A1
· Bodick et al.
· 2017
[cited by applicant]
US 20170319698A1
· Vergnault et al.
· 2017
[cited by applicant]
US 20180256606A1
· Petereit et al.
· 2018
[cited by applicant]
US 20190125678A1
· Murty et al.
· 2019
[cited by applicant]
US 20240033225A1
· Stone
· 2024
[cited by examiner]
US 20240197639A1
· Sun et al.
· 2024
[cited by applicant]
CN 101108171A
· 2008
[cited by applicant]
CN 105663091A
· 2016
[cited by applicant]
CN 110507627A
· 2019
[cited by applicant]
CN 112999229A
· 2021
[cited by applicant]
CN 115737597A
· 2023
[cited by applicant]
EP 673645A2
· 1995
[cited by applicant]
EP 0754452A2
· 1997
[cited by applicant]
EP 1125629A2
· 2001
[cited by applicant]
EP 1302200A1
· 2003
[cited by applicant]
EP 1325775A1
· 2003
[cited by applicant]
EP 1527772A1
· 2005
[cited by applicant]
EP 1622711A0
· 2006
[cited by applicant]
EP 1631373A0
· 2006
[cited by applicant]
EP 1915135A0
· 2008
[cited by applicant]
EP 1965775A0
· 2008
[cited by applicant]
EP 2278958B1
· 2012
[cited by applicant]
EP 1590144B1
· 2015
[cited by applicant]
WO 1991007172A1
· 1991
[cited by applicant]
WO 1995035100A1
· 1995
[cited by applicant]
WO 9947144A1
· 1999
[cited by applicant]
WO 0076478A1
· 2000
[cited by applicant]
WO 2008113856A1
· 2008
[cited by applicant]
WO 2009138716A1
· 2009
[cited by applicant]
WO 2010035217A1
· 2010
[cited by applicant]
WO 2010035219A2
· 2010
[cited by applicant]
WO 2010035220A1
· 2010
[cited by applicant]
WO 2010035221A1
· 2010
[cited by applicant]
WO 2011056115A1
· 2010
[cited by applicant]
WO 2012150892A1
· 2012
[cited by applicant]
WO 2013068972A1
· 2013
[cited by applicant]
WO 2015049655A1
· 2015
[cited by applicant]
WO 2015071812A1
· 2015
[cited by applicant]
WO 2015072909A1
· 2015
[cited by applicant]
WO 2016098005A1
· 2016
[cited by applicant]
WO 2016189501A1
· 2016
[cited by applicant]
WO 2019086579A1
· 2019
[cited by applicant]
WO 2020011938A1
· 2020
[cited by applicant]
WO 2020065048A1
· 2020
[cited by applicant]
WO 2021127003A1
· 2021
[cited by applicant]
WO 2022222971A1
· 2022
[cited by applicant]
Everest Medicines Announces First Patient Randomized in a Phase 3 Clinical Study of Nefecon for IgA Nephropathy Patients in China, Sep. 8, 2020—https://www.everestmedicines.com/News_detail.aspx?nid=185.
[cited by applicant]
Ismail et al., “Budesonide Versus Systemic Corticosteroids in IgA Nephropathy: A Retrospective, Propensity-matched Comparison,” Medicine 99(26):e21000 (2020).
[cited by applicant]
Raval et al., “Formulation and Evaluation of Sustained Release Enteric-coated Pellets of Budesonide for Intestinal Delivery,” Int. J. Pharm. Investig. 3(4):203-211 (2013).
[cited by applicant]
Smerud et al., “New Treatment for IgA Nephropathy: Enteric Budesonide Targeted to the Ileocecal Region Ameliorates Proteinuria,” Nephrol. Dial. Transplant 26(10):3237-3242 (2011).
[cited by applicant]
Tsuda et al., “Targeted-release Budesonide Therapy for IgA Nephropathy,” Lancet 390(10113):2625 (2017).
[cited by applicant]
Book of Abstracts, IIGANN Argentina, Kidney Dis. (Basel) 4(3):145-194 (2018).
[cited by applicant]
EU Clinical Trials Register—EudraCT No. 2017-004902-16—https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-004902-16/GB; Amsterdam, Netherlands (2018).
[cited by applicant]
Efficacy and Safety of Nefecon in Patients With Primary IgA (Immunoglobulin A) Nephropathy (Nefigard)—https://clinicaltrials.gov/ct2/show/NCT03643965?term=nefecon&draw=2; Bethesda, MD (2018).
[cited by applicant]
Levina et al., Poster Reprint of “The Effect of Hypromellose as a Pore-Former on Drug Release from Aqueous Ethylcellulose Film-Coated Dipyridamole-Loaded Non-Pareil Beads”, Controlled Release Society, Modified Release; …
[cited by applicant]
Ong et al., Poster Reprint of “Investigation of the Relationship between Formulation Variables and Drug Release in Aqueous Ethylcellulose Coating”, Controlled Release Society, Modified Release; Colorcon, West Point, PA …
[cited by applicant]
Palmer et al., Poster Reprint of “The Influence of Hydrophilic Pore Formers on Dipyridamole Release from Aqueous Ethylcellulose Film-Coated Pellets”, AAPS Annual Meeting, Modified Release; Colorcon, West Point, PA (Nov.…
[cited by applicant]
Ong et al., Poster Reprint of “Hypromellose as a Pore Former in Aqueous Ethylcellulose Dispersion: Stability and Film Properties”, AAPS Annual Meeting, Modified Release; Colorcon, West Point, PA (Nov. 2006).
[cited by applicant]
Preliminary Prospectus of Calliditas Therapeutics (without financial statements) (https://www.sec.gov/Archives/edgar/data/1795579/000110465921007672/tm2039250-2_f1.htm), Securities and Exchange Commission, Washington DC…
[cited by applicant]
Jerling et al., “Systemic GCS Exposure From Nefecon Administration, Estimated From Suppression of Endogenous Cortisol Production,” Abstract of Presentation at American Society of Nephrology 2019, Washington DC (Nov. 7, …
[cited by applicant]
Fellstrom et al., “Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial,” Lancet 389(10084):2117-2127 (2017).
[cited by applicant]
Ozturk et al., “Kinetics of Release from Enteric-coated Tablet,” Pharm. Research 5(9):550-565 (1988).
[cited by applicant]
Markopoulos et al., “In-vitro Simulation of Luminal Conditions for Evaluation of Performance of Oral Drug Products: Choosing the Appropriate Test Media,” Eur. J. Pharm. Biopharm. 93:173-182 (2015).
[cited by applicant]
Mackay et al., “Cracking the BAFF Code,” Nat. Rev. Immunol. 9:491-502 (2009).
[cited by applicant]
Schneider et al., “BAFF, a Novel Ligand of the Tumor Necrosis Factor Family, Stimulates B Cell Growth,” J. Exp. Med. 189:1747-1756 (1999).
[cited by applicant]
Yu et al., “APRIL and TALL-1 and Receptors BCMA and TACI: System for Regulating Humoral Immunity,” Nat. Immunol. 1:252-256 (2000).
[cited by applicant]
Steri et al., “Overexpression of the Cytokine BAFF and Autoimmunity Risk,” N. Engl. J. Med. 376:1615-1626 (2017).
[cited by applicant]
Barratt et al., “Treatment of IgA Nephropathy: Evolution Over Half a Century,” Semin. Nephrol. 38(5):531-540 (2018).
[cited by applicant]
Seikrit et al., “The Immune Landscape of IgA Induction in the Gut,” Semin. Immunopathol. 43:627-637 (2021).
[cited by applicant]
Boyd et al., “An Update on the Pathogenesis and Treatment of IgA Nephropathy,” Kidney Int. 81:833-843 (2012).
[cited by applicant]
Klein, “The Use of Biorelevant Dissolution Media to Forecast the In Vivo Performance of a Drug,” Aaps J. 12:397-406 (2020).
[cited by applicant]
Molyneux et al., Abstract of Presentation from ERA-EDTA Symposium 2020, “Nefecon® (Budesonide) selectively reduces circulating levels of BAFF (BLyS) and soluble BCMA and TACI in IgA Nephropathy,” Nephrology Dialysis Tra…
[cited by applicant]
Barratt et al., Abstract of Presentation from ERA-EDTA Symposium 2020, “The Nefigard Trial: The Effect of Nefecon® (Budesonide) in Patients With Primary IgA Nephropathy at Risk of Developing End-stage Renal Disease,” Ne…
[cited by applicant]
Fellstrom et al., Title of Presentation from The Lancet/ERA-EDTA Symposium 2017, “Effects of a Novel Targeted Release Formulation of Budesonide vs. Placebo in IgA Nephropathy: The NEFIGAN Randomised Clinical Trial” (Jun…
[cited by applicant]
Fellstrom et al., Abstract of Presentation at ERA-EDTA Symposium 2017, “Proteinuria Reduction in IgA Nephropathy by Nefecon, a Targeted Release Formulation of Budesonide—Results From the NEFIGAN Trial,” Nephrology Dialy…
[cited by applicant]
Selvaskandan et al., “New Strategies and Perspectives on Managing IgA Nephropathy,” Clin. Exp. Nephrol. 23 (5):577-588 (2019).
[cited by applicant]
Cheung et al., “An Update on the Current State of Management and Clinical Trials for IgA Nephropathy,” J. Clin. Med. 10(11):2493 (2021).
[cited by applicant]
Chang et al., “The Role of Immune Modulation in Pathogenesis of IgA Nephropathy,” Front. Med. 7:92 (2020).
[cited by applicant]
Novak et al., “New Insights into the Pathogenesis of IgA Nephropathy,” Kidney Dis. (Basel) 1(1):8-18 (2015).
[cited by applicant]
Barratt et al., “Why Target the Gut to Treat IgA Nephropathy?,” Kidney Int. Rep. 5(10):1620-1624 (2020).
[cited by applicant]
Kiryluk et al., “The Genetics and Immunobiology of IgA Nephropathy,” J. Clin. Invest. 124(6):2325-32 (2014).
[cited by applicant]
Wilson et al., “Chapter 3—Gastrointestinal Transit and Drug Absorption” In: “Oral Drug Absorption: Prediction and Assessment”, 2nd Edition, Edited by J. Dressman and C. Reppas, Drug and the Pharmaceutical Sciences vol. …
[cited by applicant]
Hammers D. W., “Nox4 Inhibition Promotes the Remodeling of Dystrophic Muscle,” JCI Insight 7(20):e158316 (2022) Also published on bioRxiv, doi: https://doi.org/10.1101/2022.01.08.475493.
[cited by applicant]
Hammers D., Abstract of Poster 18, Presentation at MDA Conference 2021, “Nox4 Inhibition Reduces Skeletal Muscle Fibrosis in a Severe Murine Model of Duchenne Muscular Dystrophy,” (2021) (available at: https://www.mdaco…
[cited by applicant]
Augsburger et al., “Pharmacological Characterization of the Seven Human NOX Isoforms and Their Inhibitors,” Redox Biol. 26:101272 (2019).
[cited by applicant]
Ismail H. M., “Diapocynin, a Dimer of the NADPH Oxidase Inhibitor Apocynin, Reduces ROS Production and Prevents Force Loss in Eccentrically Contracting Dystrophic Muscle,” Plos One 9(10): e110708 (2014).
[cited by applicant]
Watts et al., “TARGIT Technology: Coated Starch Capsules for Site-specific Drug Delivery Into the Lower Gastrointestinal Tract,” Expert Opin. Drug. Deliv. 2(1):159-167 (2005).
[cited by applicant]
Inker et al., “Early Change in Urine Protein as a Surrogate End Point in Studies of IgA Nephropathy: An Individual- Patient Meta-analysis, ”Am. J. Kidney Dis. 68(3):392-401 (2016).
[cited by applicant]
Kobayashi et al., “The Roles of Peyer's Patches and Microfold Cells in the Gut Immune System: Relevance to Autoimmune Diseases,” Front. Immunol. 10:2345 (2019).
[cited by applicant]
Miller et al., “Chapter 12 - Aqueous Polymeric Film Coating” In: “Pharmaceutical Dosage Forms: Tablets”, 3rd Edition, vol. 1: Unit Operations and Mechanical Properties, Edited by L. L. Augsburger and S. W. Hoag; ISBN 97…
[cited by applicant]
Rekhi et al., “Bioavailability and In-vitro/in-vivo Correlation for Propranolol Hydrochloride Extended-release Bead Products Prepared Using Aqueous Polymeric Dispersions,” J. Pharm. Pharmacol. 48:1276-1284 (1996).
[cited by applicant]
Kosztyu et al., “Glucocorticoids Reduce Aberrant O-Glycosylation of IgA1 in IgA Nephropathy Patients,” Kidney Blood Press. Res. 43:350-359 (2018).
[cited by applicant]
Seidegard et al., “Presystemic Elimination of Budesonide in Man When Administered Locally at Different Levels in the Gut, With and Without Local Inhibition by Ketoconazole,” Eur. J. Pharm. Sci. 35(4):264-270 (2008).
[cited by applicant]
Raje et al., “Evaluation of Separate Role of Intestine and Liver in First Pass Metabolism of Budesonide in Fat,” Xenobiotica 48(12):1206-1214 (2018).
[cited by applicant]
Gesualdo et al., “The Mucosal Immune System and IgA Nephropathy,” Semin. Immunopathol. 43:657-668 (2021).
[cited by applicant]
Coppo R., “The Gut-Renal Connection in IgA Nephropathy,” Semin. Nephrol. 38:504-512 (2018).
[cited by applicant]
O'Grady et al., “Defining Gastrointestinal Transit Time Using Video Capsule Endoscopy: A Study of Healthy Subjects,” Endoscopy Int. Open 08:E396-E400 (2020).
[cited by applicant]
Sager et al., “Low Dose Caffeine as a Salivary Tracer for the Determination of Gastric Water Emptying in Fed and Fasted State: A MRI Validation Study,” Eur. J. Pharm. Biopharm. 127:443-452 (2018).
[cited by applicant]
Newton et al., “Plasma and Salivary Pharmacokinetics of Caffeine in Man,” Eur. J. Clin. Pharmacol. 21:45-52 (1981).
[cited by applicant]
Molyneux et al., Abstract of Poster Presentation at American Society of Nephrology (ASN) Annual Kidney Week 2021 Conference, “Targeted Release Formulation Budesonide (Nefecon) Selectively Reduces Circulating Levels of C…
[cited by applicant]
Perez-Alos et al., Abstract of Poster Presentation at American Society of Nephrology (ASN) Annual Kidney Week 2021 Conference, “Treatment with Targeted Release Formulation Budesonide (Nefecon) Modulates the Complement S…
[cited by applicant]
Seikrit et al., Abstract of Poster Presentation from Proceedings of 16th International Symposium on IgA Nephropathy IgA Nephropathy 2021, “Analysis of the Effect of TRF-Budesonide (Nefecon) on Urinary sCD163 in Patients…
[cited by applicant]
Maixnerova et al., Abstract of Poster Presentation from Proceedings of 16th International Symposium on IgA Nephropathy IgA Nephropathy 2021, “TRF-budesonide (Nefecon) Positively Impacts Serum and Urinary Biomarkers Invo…
[cited by applicant]
Stone et al., Abstract of Poster Presentation from Proceedings of 16th International Symposium on IgA Nephropathy IgA Nephropathy 2021, “eGFR Slope at 1 Year May Independently Predict Clinical Benefit in Patients With I…
[cited by applicant]
Bhachu et al., Abstract of Poster Presentation from Proceedings of 15th International Symposium on IgA Nephropathy IgA Nephropathy 2018, “Targeted Release-Budesonide (Nefecon) Modifies Circulating IGA-IGG Immune Complex…
[cited by applicant]
Muto et al., Abstract of Poster Presentation from Proceedings of 15th International Symposium on IgA Nephropathy IgA Nephropathy 2018, “Targeted Release-Budesonide (NEFECON) Modifies Mucosal IgA Responses and Possibly G…
[cited by applicant]
Soares et al., Abstract of Poster Presentation from Proceedings of 15th International Symposium on IgA Nephropathy IgA Nephropathy 2018, “Extent of Segmental Glomerulosclerosis in IgA Nephropathy is Associated With the …
[cited by applicant]
Fellstrom et al., Abstract of Poster Presentation from Proceedings of 15th International Symposium on IgA Nephropathy IgA Nephropathy 2018, “Treatment of IgA Nephropathy With Nefecon, a Targeted release Formulation of F…
[cited by applicant]
Haggblad et al., Abstract of Poster Presentation from Proceedings of 15th International Symposium on IgA Nephropathy IgA Nephropathy 2018, “Nefecon, an Oral Disease Modifying Treatment for Progressive IgA Nephropathy. T…
[cited by applicant]
International Search Report and Written Opinion for PCT/EP2023/051680, mailed Mar. 29, 2023.
[cited by applicant]
Press Release, Calliditas Therapeutics, “Pharmalink AB receives patent for Nefecon® principle. Japanese grant supports Asian partnering program,” Oct. 26, 2009 (available at https://www.calliditas.se/en/pharmalink-ab-re…
[cited by applicant]
Press Release, Fierce Biotech, “Pharmalink AB Gains Exclusive Licence to Archimedes Pharma's TARGIT® Technology for Nefecon® (PL-56) Program,” Dec. 13, 2011 (available at https://www.fiercebiotech.com/biotech/pharmalink…
[cited by applicant]
Press Release, Calliditas Therapeutics, “Pharmalink enters manufacturing agreement for Nefecon®,” Oct. 31, 2012 (available at https://www.calliditas.se/en/pharmalink-enters-manufacturing-agreement-for-nefecon/).
[cited by applicant]
Press Release, Calliditas Therapeutics, “Pharmalink's core patents for Nefecon® treatment for renal disease granted in United States, Europe, China and Hong Kong,” Jul. 10, 2014 (available at https://www.calliditas.se/e…
[cited by applicant]
Press Release, PRESSMEDDELANDE, “Pharmalink AB Receives US Orphan Drug Designation for Nefecon® (PL-56),” Oct. 13, 2010 (available at https://www.mynewsdesk.com/se/pharmalink-ab/pressreleases/pharmalink-ab-receives-us-o…
[cited by applicant]
Press Release, Calliditas Therapeutics, “Pharmalink initiates a pivotal Phase IIb trial with Nefecon® in patients with primary IgA nephropathy,” Dec. 18, 2012 (available at https://www.calliditas.se/en/pharmalink-initia…
[cited by applicant]
Prospectus of Calliditas Therapeutics (without financial statements) (available at https://www.sec.gov/Archives/edgar/data/1795579/000110465920070680/tm2019773-4_424b4.htm), Securities and Exchange Commission, Washingto…
[cited by applicant]
Vecchio et al., “Nefecon (targeted-release formulation budesonide) for the treatment of IgA nephropathy,” Future Rare Diseases, 1(4) (Dec. 2021).
[cited by applicant]
Tatematsu et al., “Complete remission within 2 years predicts a good prognosis after methylprednisolone pulse therapy in patients with IgA nephropathy,” Clinical and Experimental Nephrology, Springer-Verlag, 16(6):883-8…
[cited by applicant]
Gharavi et al., “IgA Nephropathy, the Most Common Cause of Glomerulonephritis, is Linked to 6q22-23,” Nature Genetics 26:354-357 (2000).
[cited by applicant]
Office Action in U.S. Appl. No. 18/100,396, mailed Mar. 31, 2023.
[cited by applicant]
Office Action in U.S. Appl. No. 18/100,396, mailed Jul. 17, 2023.
[cited by applicant]